Technology FDA Approves Phase 2 Trial for Novel Anti-Fibrotic Drug AK3280 On February 12, 2026, the U.S. Food and Drug Administration (FDA) granted clearance for Shanghai Ark Biopharmaceutical Co., Ltd. to initiate a Phase 2... Editorial12 February, 2026